Guggenheim analyst Michael Schmidt lowered the firm’s price target on Immunome (IMNM) to $25 from $35 and keeps a Buy rating on the shares after updating the firm’s model to reflect Q4 results. The firm cites stock dilution following the recent financing in Q1, partially offset by incrementally increased odds of success seen for IM-1021 following positive data from Merck’s (MRK) MK-2140 program in December for its revised price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue